International Review of Ophthalmology ›› 2024, Vol. 48 ›› Issue (2): 139-144.doi: 10.3760/ cma.j.issn.1673-5803.2024.02.011

Previous Articles     Next Articles

The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy

Lv Panpan1, Hao Rui1,2   

  1. 1Nankai University Affiliated Eye Hospital, Tianjin 300020, China; 2Tianjin Eye Hospital, Tianjin Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin 300020, China
  • Received:2023-12-09 Online:2024-04-22 Published:2024-04-22
  • Contact: Hao Rui, Email: haorui0311@126.com
  • Supported by:
     Tianjin Health Science and Technology Fund General Project (TJWJ2021MS041); Tianjin Medical Key Discipline (Specialized) Construction Project (TJYXZDXK-016A); Tianjin Health Industry High level Talent Plan (Young Medical Emerging) (TJSQNYXXR-D2-137)

Abstract: The pathogenic mechanisms of thyroid-associated ophthalmopathy (TAO) have not been fully elucidated. Overexpression of  insulin-like growth factor 1 receptor (IGF-1R) plays a certain promoting role in the pathogenesis of TAO, and the use of its inhibitor, teprotumumab, can exert an inhibitory effect on the clinical manifestations and progression of TAO. Elevated levels of immunoglobulin G and beta-blocking protein in the serum of TAO patients can regulate the expression or function of IGF-1R, promoting the clinical manifestations and progression of TAO. In 2020, teprotumumab became the first drug approved by the U.S. FDA for the treatment of TAO, and the implementation of targeted anti-IGF-1R therapy and related clinical trials have laid the foundation for studying the role of IGF-1R in the pathogenesis of TAO and targeted therapy for TAO.  (Int Rev Ophthalmol, 2024, 48: 139-144)

Key words: insulin-like growth factor-receptor, thyroid-associated ophthalmopathy